Stocks and Investing
Stocks and Investing
Fri, July 21, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Paul Choi Maintained (VIR) at Strong Buy with Decreased Target to $28 on, Jul 21st, 2023
Paul Choi of Goldman Sachs, Maintained "Vir Biotechnology, Inc." (VIR) at Strong Buy with Decreased Target from $51 to $28 on, Jul 21st, 2023.
Paul has made no other calls on VIR in the last 4 months.
There are 2 other peers that have a rating on VIR. Out of the 2 peers that are also analyzing VIR, 0 agree with Paul's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Paul
- Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $22 on, Thursday, July 20th, 2023
- Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $100 on, Thursday, July 20th, 2023
Contributing Sources